Search ABOUT PROGRAMS PLATFORM NEWS PUBLICATIONS INVESTORS CAREERS CONTACT TOGETHER WE... TOGETHER WE… believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease. BELIEVE ACHIEVE Nov 24, 2021 | Regulus Therapeutics Announces Private Placement of Equity » Nov 10, 2021 | Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates » Nov 03, 2021 | Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call » microRNA MOA © 2021 Regulus Therapeutics Inc. - All Rights Reserved Home | Legal | Contact

Search ABOUT PROGRAMS PLATFORM NEWS PUBLICATIONS INVESTORS CAREERS CONTACT BELIEVE ACHIEVE MANAGEMENT Management Jay Hagan President and Chief Executive Officer Cris Calsada Chief Financial Officer Christopher Aker, J.D. Senior Vice President and General Counsel Denis Drygin, Ph.D. Chief Scientific Officer JAY HAGAN President and Chief Executive Officer Mr. Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing Director of Amgen Ventures and head of corporate development for Amgen Inc. Mr. Hagan has led numerous strategic and financing transactions including the acquisitions of Immunex and Tularik and the spinout of Novantrone and Relyspa, as well as many other business development efforts totaling over $15 billion in value. Before joining Amgen, Mr. Hagan spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences. Mr. Hagan currently serves on the board of directors of Zosano Pharma, a publicly traded biotechnology company. He received an M.B.A. from Northeastern University and a B.S. in Physiology and Neuroscience from the University of California, San Diego © 2021 Regulus Therapeutics Inc. - All Rights Reserved Home | Legal | Contact

Skip to main navigation Search ABOUT PROGRAMS PLATFORM NEWS PUBLICATIONS INVESTORS CAREERS CONTACT Shareholder Tools ACHIEVE INVESTMENT CALCULATOR Investment Month January Investment Day 2 Investment Year 2014 Investment Units Shares INVESTMENT DATE ORIGINAL SHARES ORIGINAL VALUE CURRENT SHARES CURRENT VALUE % RETURN SPLIT ADJUSTMENT CURRENT PRICE Jan 02, 2014 1,000.00 $613.33 83.33 $34.25 -94.42% 0.08333 $0.41 Return calculations do not include reinvested cash dividends. © 2021 Regulus Therapeutics Inc. - All Rights Reserved Home | Legal | Contact